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Therapy for Alopecia Areata in Mice by
Stimulating the Hair Cycle with Parathyroid
Hormone Agonists Linked to a Collagen-Binding
Domain
Ranjitha Katikaneni1, Andrew W. Seymour2, Rohan Gulati1, Tulasi Ponnapakkam1 and Robert C. Gensure1
Alopecia areata is a common disorder in which autoimmune destruction of hair follicles results in patchy hair
loss. Currently there is no adequate therapy, although immune modulator therapies are currently in develop-
ment. Parathyroid hormone (PTH) is a hair cycle stimulator which shows promise in treating various forms of
alopecia, although its short half-life limits its clinical use. PTH-CBD is a PTH analog which binds collagen,
prolonging retention in skin. We tested effects of PTH-CBD in C3H/HeJ-engrafted mice, the animal model for
alopecia areata, on hair growth and found that a significant proportion of animals had reduced hair loss (PTH-
CBD: 13/21, 62% vs. control: 3/10, 30%; Po0.01). Histological analysis showed no change in immune response, but
there was increased number of anagen hair follicles and increased production of beta-catenin, a factor which
initiates the anagen phase of the hair cycle. PTH-CBD thus shows promise as a therapy for alopecia areata, either
alone or in conjunction with immune modulation therapy.
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INTRODUCTION
Alopecia areata is a common form of hair loss which affects
2.1% of population (Mirzoyev et al., 2013). It is caused by a
T-cell–mediated autoimmune destruction of anagen phase
hair follicles, resulting in patchy hair loss (Luet al., 2006). It
can progress to alopecia totalis (total loss of hair on the head)
or alopecia universalis (loss of all hair on body). Currently
there is no adequate therapy, but therapies based on immune
modulation, specifically by inhibiting Janus kinases, are in
development (Divito and Kupper 2014). Hair cycle stimulators
represent an alternate therapeutic approach, by directly
stimulating replacement of damaged hair follicles.
Parathyroid hormone (PTH) is once such hair cycle
stimulator, but its short half-life limits its therapeutic use
(Gensure, 2014). PTH-CBD is a fusion protein of the active
portion of PTH, PTH(1–33), linked to a bacterial collagen-
binding domain (CBD) derived from ColH collagenase
(Clostridium histolyticum). The CBD results in prolonged
retention in collagen-containing tissues, including skin
(Katikaneni et al., 2012). PTH-CBD has been shown in
animal models to be effective in treating chemotherapy-
induced alopecia (Katikaneni et al., 2014).
RESULTS AND DISCUSSION
We tested the effects of subcutaneous administration of PTH-
CBD on hair loss in C3H/HeJ-engrafted mice (Jackson Labora-
tories, Bar Harbor, ME), and found that a significantly greater
proportion of animals retained their hair for 8 weeks after a
single dose (PTH-CBD: 13/21, 62% vs. control: 3/10, 30%;
Po0.01). Histological examination revealed an increased
number of anagen hair follicles and reduced hair follicle
dystrophy after PTH-CBD therapy (Figure 1). Immunohisto-
chemistry showed no change in CD8þ cells surrounding the
hair follicles after PTH-CBD treatment, consistent with an
ongoing immune response. There were, however, increased
levels of beta-catenin in the approximate area of the bulge of
the hair follicles (Figure 1).
It appears that PTH-CBD reduces hair loss in C3H/HeJ mice
not by modulation of the immune response, but rather by
direct stimulation of the hair cycle by increasing levels of beta-
catenin. PTH has been described as modulating beta-catenin
expression in many tissues, including in a model of PTHrP
overexpression in skin (Foley et al., 2001), and in skin
increased beta-catenin expression directs hair follicles to
enter the anagen phase (Huelsken et al., 2001). PTH has
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also been described as promoting anagen-to-catagen
transitions in skin (Cho et al., 2003), thus increasing the
speed of the hair cycle at multiple levels. On the other hand,
while all animals showed increased number of anagen hair
follicles after PTH-CBD treatment, not all treated animals
responded with decreased hair loss, suggesting that other
factors (i.e., degree of immune response) influence
the net effect of therapy on hair growth. This suggests that a
combination therapy of PTH-CBD and an immune modulator
might result in a more uniform response.
On the basis of these encouraging results, efforts are
now underway to optimize this therapy by increasing the
collagen-binding affinity to improve retention at the site
of the administration, and by developing a topical formulation,
which would provide a more convenient method of
administration.
MATERIALS AND METHODS
In all 40 C3H/HeJ mice were engrafted with donor skin from a mouse
with autoimmune hair loss and observed for 30 days (partial hair loss).
Mice were then stratified by the degree of hair loss and divided into
groups receiving either vehicle control, one of several doses of PTH-
CBD (320 mcg s.q. x1, 1,000 mcg s.q. x1, or 1,000 mcg s.q per
week 8 weeks), or the antagonist PTH(7–33)-CBD (320 mcg kg 1).
Mice were photographed and observed weekly for 8 weeks
and for degree of hair loss. Proportion of mice with hair loss were
compared between groups by w2 analysis. Mice were then killed
and skin samples were prepared by flash-freezing for histological
analysis. Skin were processed for hematoxylin and eosin staining,
immunohistochemistry for CD8 expression, or immunohistochemistry
for beta-catenin expression (Figure 1).
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Figure 1. Gross and histological appearance of representative C3H/HeJ-engrafted mice after administration of parathyroid hormone (PTH)-collagen-binding
domainCBD or vehicle control. Shown are the photographs of the dorsal surface of the mouse, hematoxylin and eosin staining (H&E) staining of full-thickness skin
sections, immunohistochemistry for CD8þ cells in skin, and immunohistochemistry for beta-catenin in skin for a vehicle control animal with no hair loss (1), a
vehicle control animal with significant hair loss (2), and a PTH-CBD treated animal with no hair loss (3). In immunohistochemistry analyses, areas of antibody
binding appear as brown staining.
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